Aktis Oncology, Inc. targets $200M IPO to advance radiopharmaceuticals for solid tumors. Click for more on the upcoming AKTS ...
Aktis Oncology (AKTS), a radiopharmaceutical drug developer that counts Eli Lilly (LLY) among its partners, filed SEC filings ...
WEST CHESTER, Pa., December 09, 2024--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI) published preclinical study results for their proprietary 225 Ac-EBTATE against SSTR2 NET cancers ...
HAMILTON, ON, Nov. 12, 2025 /CNW/ - AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical CDMO, announced that it has successfully supplied the first dose of Ariceum Therapeutics' ...
225Ac-SSO110 has received U.S. FDA Orphan Drug Designation Initial safety data from SANTANA-225 in ES-SCLC and MCC expected in 2026 Potential to address a broad range of neuroendocrine cancers BERLIN, ...
Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation for 225Ac-FL-020, ...
Activity of lutetium-177 PSMA (Lu-PSMA) and determinants of outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with cabazitaxel: The PACAP study. This ...
Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, announced that the US Food and Drug ...
SSO-110, also known as DOTA-JR11 or satoreotide tetraxetran, is a somatostatin SST2 receptor (SSTR2) antagonist that targets a higher number of binding sites and stays longer in SSTR2-positive tumors ...
BERLIN, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Ariceum Therapeutics (Ariceum), a targeted radiotherapeutics company dedicated to setting new standards in cancer care, today announced that the first patient ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback